Expanded Access to Triheptanoin

NCT ID: NCT03773770

Last Updated: 2026-01-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

AVAILABLE

Study Classification

EXPANDED_ACCESS

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Expanded access may be provided for qualified patients who have limited treatment options and are not eligible for a clinical trial.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Long Chain Fatty Acid Oxidation Disorders (LC-FAOD) and other Non-FAOD conditions, where applicable: Expanded access may be available outside of the US in countries prior to approval by the local regulatory agencies.

For full details, please visit the links provided below.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Long Chain Fatty Acid Oxidation Disorders

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Triheptanoin

Liquid for oral (PO) or enteral tube administration

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

UX007

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

\- The participant must not be eligible for a UX007 clinical trial
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ultragenyx Pharmaceutical Inc

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Medical Director

Role: STUDY_DIRECTOR

Ultragenyx Pharmaceutical Inc

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Early Access

Role: CONTACT

1-415-483-8800

Related Links

Access external resources that provide additional context or updates about the study.

https://www.dojolvi.com/

Dojolvi Patient and Prescribing Information Page

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

UX007-EAP

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Response to Clenbuterol in Humans
NCT03860870 COMPLETED NA
Inhaled Fentanyl Citrate & Dyspnea
NCT01853449 COMPLETED EARLY_PHASE1